Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha kinoid - Neovacs

Drug Profile

Interferon alpha kinoid - Neovacs

Alternative Names: CKD-971; IFNalpha kinoid vaccine - Neovacs; IFNα-kinoid

Latest Information Update: 05 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neovacs
  • Developer Department Immunology of Diabetes at Hospital Cochin; Neovacs; sanofi pasteur
  • Class Anti-inflammatories; Antihyperglycaemics; Interferons; Recombinant fusion proteins; Skin disorder therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Dermatomyositis; Systemic lupus erythematosus

Highest Development Phases

  • Phase II Dermatomyositis; Systemic lupus erythematosus
  • No development reported Type 1 diabetes mellitus
  • Discontinued HIV infections; Sjogren's syndrome

Most Recent Events

  • 05 Feb 2024 Neovacs completes a phase IIb trial forSystemic Lupus Erythematosus in USA, Argentina, Belgium, Chile, Colombia, Croatia, France, Georgia, Germany, Italy, South Korea, Mexico, Moldova, Peru, Philippines, Poland, Russia, Switzerland, Taiwan, Thailand, Tunisia (IM, Injection) (NCT02665364) (EudraCT2015-001341-86) (Neovacs pipeline, January 2024)
  • 13 Mar 2023 BioSense Global plans to file an IND application with the NMPA in China for phase IIb trial in Systemic lupus erythematosus
  • 13 Mar 2023 BioSense Global plans a phase IIb trial in Systemic lupus erythematosus in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top